<?xml version="1.0" encoding="UTF-8"?>
<p>The Zika virus, discovered in Uganda in 1947 [
 <xref rid="B1-tropicalmed-04-00104" ref-type="bibr">1</xref>], was shown to be endemic through Sub-Saharan Africa and tropical areas of Southeastern Asia in studies through the second half of the 20th century [
 <xref rid="B2-tropicalmed-04-00104" ref-type="bibr">2</xref>]. Isolated outbreaks occurred in Yap Island in 2007 [
 <xref rid="B3-tropicalmed-04-00104" ref-type="bibr">3</xref>] and on French Polynesia in 2014 [
 <xref rid="B4-tropicalmed-04-00104" ref-type="bibr">4</xref>]. Starting in mid-2015, Zika virus infection achieved epidemic status, spreading rapidly through South America, Central America, and the Caribbean Islands [
 <xref rid="B5-tropicalmed-04-00104" ref-type="bibr">5</xref>]. It was soon recognized that Zika virus infection occurring during pregnancy caused microcephaly and other congenital disorders in the developing fetus, the latter being the primary reason for the World Health Organization (WHO) labelling Zika as an international threat in early 2016. Beginning in late 2015, numerous academic labs and pharmaceutical companies initiated work to develop a vaccine against Zika, however, by the time the first vaccines entered clinical trials, the Zika epidemic had started to wane creating significant challenges to vaccine assessment [
 <xref rid="B6-tropicalmed-04-00104" ref-type="bibr">6</xref>] that has engendered discussion of other regulatory pathways to licensure [
 <xref rid="B7-tropicalmed-04-00104" ref-type="bibr">7</xref>].
</p>
